BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 134897
- Registration Number
- NCT04249401
- Locations
- 🇸🇪
Many locations, Multiple Locations, Sweden
Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration
- Conditions
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04236440
- Locations
- 🇦🇺
Adelaide Institute for Sleep Health, Bedford Park, South Australia, Australia
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 194
- Registration Number
- NCT04232761
- Locations
- 🇨🇳
Many locations, Multiple Locations, Taiwan
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
- Conditions
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 755
- Registration Number
- NCT04218266
- Locations
- 🇫🇷
Hôpital de Rangueil - Toulouse, Toulouse, France
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇸🇪Danderyds sjukhus, Stockholm, Sweden
Survey on Belgian Patients Suffering From Irregular Heartbeat and Starting Treatment With a Drug to Prevent Blood Clots in Blood Vessels and the Heart. This Study is Also Called BELANCOS.
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 164
- Registration Number
- NCT04183270
- Locations
- 🇧🇪
Many locations, Multiple Locations, Belgium
Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 812
- Registration Number
- NCT04174859
- Locations
- 🇮🇹
Many locations, Multiple Locations, Italy
A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 468
- Registration Number
- NCT04162795
- Locations
- 🇺🇸
Focus Pointe Global, Teaneck, New Jersey, United States
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT04157088
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Maine, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸MidLantic Urology - Bala Cynwyd, Bala-Cynwyd, Pennsylvania, United States
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04147819
- Locations
- 🇺🇸
Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT04142437
- Locations
- 🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
🇺🇸Gundersen Health System, La Crosse, Wisconsin, United States